Phenotypeca psoriasis VHH antibody

Phenotypeca's psoriasis VHH antibody is a single-domain antibody (also known as a nanobody) currently in development for the treatment of psoriasis. This therapeutic candidate is produced using Phenotypeca's proprietary yeast-based (*Saccharomyces cerevisiae*) expression platform, which is designed to provide a high-yield, scalable, and cost-effective alternative to traditional mammalian cell culture. VHH antibodies are derived from the variable regions of heavy-chain-only antibodies found in camelids; their small size (approximately 15 kDa) and high stability potentially allow for better tissue penetration and the possibility of topical delivery, which is highly relevant for dermatological conditions like psoriasis. While the specific molecular target (e.g., IL-17, IL-23) has not been disclosed, the asset represents a key part of Phenotypeca's internal pipeline of optimized biologics.

Other names

VHH antibody (psoriasis)Phenotypeca psoriasis single-domain antibody